聚乙二醇化重组人粒细胞刺激因子在造血干细胞移植后促进造血恢复的疗效分析

doi:10.3969/j.issn.1000-8535.2022.06.012

广州医药 ›› 2022, Vol. 53 ›› Issue (6): 56-60.DOI: 10.3969/j.issn.1000-8535.2022.06.012

聚乙二醇化重组人粒细胞刺激因子在造血干细胞移植后促进造血恢复的疗效分析

张晓瀚, 陈诗彧, 汪鹏程, 蔡云, 杜新

深圳市第二人民医院 (深圳 518053)

收稿日期:2021-10-20 出版日期:2022-11-20 发布日期:2022-11-30

Treatment outcome of pegylated recombinant human granulocyte colony stimulating factor to promote hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation(allo-HSCT)

ZHANG Xiaohan, CHEN Shiyu, WANG Pengcheng, CAI Yun, DU Xin

The Second People's Hospital of Shenzhen, Shenzhen 518053, China

Received:2021-10-20 Online:2022-11-20 Published:2022-11-30

摘要/Abstract

摘要： 目的观察聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)与重组人粒细胞刺激因子(rhG-CSF)在造血干细胞移植后促进造血恢复的疗效对比。方法回顾分析2016年1月—2020年12月以来在深圳市第二人民医院血液科进行造血干细胞移植的恶性血液疾病患者共 100例,随机分为2组,分别在造血干细胞回输后给与聚乙二醇化重组人粒细胞刺激因子与重组人粒细胞刺激因子。结果 PEG-rhG-CSF组与rhG-CSF组中性粒细胞植入时间分别为(18.7±3.4)天、(18.0±3.1)天,P=0.281,无统计学差异。粒细胞缺乏伴发热在PEG-rhG-CSF组与rhG-CSF组分别发生26例、29例,发生率分别为53.06%、56.86%,P=0.89,无差异。用药次数分别为2.6次(2~5次)、18.1次(11~31次),P<0.05,差异有统计学意义。不良反应主要为骨痛、肌肉疼痛。结论 PEG-rhG-CSF组与rhG-CSF组结果相似,PEG-rhG-CSF具有用药次数少的优势。

关键词: 聚乙二醇化重组人粒细胞刺激因子, 造血干细胞移植, 重组人粒细胞刺激因子, 造血恢复

Abstract: Objective The efficacy of pegylated recombinant human granulocyte stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte stimulating factor(rhG-CSF) in promoting hematopoiesis recovery after hematopoietic stem cell transplantation.Methods The data of 100 patients with malignant blood diseases who underwent hematopoietic stem cell transplantation in the Hematology Department of Shenzhen Second People's Hospital from January 2016 to December 2020 were retrospectively analyzed.They were randomly assigned to two groups,which accepted PEG-rhG-CSF and rhG-CSF respectively after hematopoietic stem cell transfusion.Results The time of neutrophil implantation in PEG-rhG-CSF group and rhG-CSF group were (18.7±3.4) days and (18.0±3.1) days respectively,P=0.281,showing no statistical difference.There were 26 cases of neutropenia with fever in PEG-rhG-CSF group and 29 cases in rhG-CSF group,with incidence of 53.06% and 56.86% (P=0.89),showing no statistical difference.The times of medication were 2.6 times (2-5 times) and 18.1 times (11-31 times),P<0.05,with significant statistical difference.The main adverse reactions were bone pain and muscle pain.Conclusions The outcomes of PEG-rhG-CSF group and rhG-CSF group were similar,PEG-rhG-CSF had the advantage of fewer times of medication.

Key words: PEG-rhG-CSF, hematopoietic stem cell transplantation, rhG-CSF, hematopoiesis recovery

张晓瀚, 陈诗彧, 汪鹏程, 蔡云, 杜新. 聚乙二醇化重组人粒细胞刺激因子在造血干细胞移植后促进造血恢复的疗效分析[J]. 广州医药, 2022, 53(6): 56-60.

ZHANG Xiaohan, CHEN Shiyu, WANG Pengcheng, CAI Yun, DU Xin. Treatment outcome of pegylated recombinant human granulocyte colony stimulating factor to promote hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation(allo-HSCT)[J]. Guangzhou Medical Journal, 2022, 53(6): 56-60.

参考文献

[1] WEAVER C H,SCHWARTZBERG L S,HAINSWORTH J,et al.Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers[J].Bone Marrow Transplant,1997,19(7):671-678.
[2] KUBO K,MIYAZAKI Y,MURAYAMA T,et al.A randomized,double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R)chemotherapy for malignant lymphoma[J].Br J Haematol,2016,174(4):563-570.
[3] QIN Y,HAN X,WANG L,et al.A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia[J].Chin J Cancer Res,2017,29(5):402-410.
[4] VANSTRAELEN G,FRRE P,NGIRABACU M C,et al.Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation[J].Exp Hematol,2006,34(3):382-388.
[5] BATTIWALLA M,MCCARTHY P L.Filgrastim support in allogeneic HSCT for myeloid malignancies: a review of the role of G-CSF and the implications for current practice[J].Bone Marrow Transplant,2009,43(5):351-356.
[6] BISHOP M R,TARANTOLO S R,GELLER R B,et al.A randomized,double-blind trial of filgrastim(granulocyte colony-stimulating factor)versus placebo following allogeneic blood stem cell transplantation[J].Blood,2000,96(1):80-85.
[7] 徐兵河,宋艳秋,王京芬,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对照Ⅱ期临床研究[J].中国肿瘤临床与康复,2016,23(1):3-7.
[8] 李晓燕,潘莹,魏雪,等.聚乙二醇化重组人粒细胞刺激因子致白细胞增多的国内外文献分析[J].中国医院药学杂志,2018,38(24):2580-2583.
[9] YANG B B,KIDO A .Pharmacokinetics and pharmacodynamics of pegfilgrastim[J].Clin Pharmacokinet,2011,50(5):295-306.
[10] 张春云,邵杰,吴雅丽,等.聚乙二醇化重组人粒细胞集落刺激因子注射液在健康志愿者中的药动学和药效学研究[J].现代药物与临床,2017,32(9):1614-1619.
[11] GERDS A,FOX-GEIMAN M,DAWRAVOO K,et al.Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation[J].Biol Blood Marrow Transplant,2010,16(5):678-685.
[12] 马军,朱军,徐兵河,等.聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)临床应用中国专家共识[J].中国肿瘤临床,2016,43(7):271-274.
[13] 刘凯奇,王迎,赵姿,等.初诊急性髓系白血病诱导治疗后聚乙二醇化重组人G-CSF与普通重组人G-CSF促进中性粒细胞恢复的单中心随机对照研究 [J].中华血液学杂志,2019,40 (6): 497-501.
[14] 张永娜,贺宝霞,张振鑫,等.短效与长效粒细胞刺激因子用于恶性肿瘤化疗所致骨髓抑制的疗效及成本-效果分析[J].中国医院药学杂志,2020,40(20):59-63.
[15] 范志松,邢栋,董志杰,等.粒细胞集落刺激因子引发骨痛的机制及其治疗的研究进展[J].中国新药与临床杂志.2020,39(7):390-393.
[16] TIMMER-BONTE J,OUWERKERK J,FABER L M,et al.Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients[J].Neth J Med,2020,78(5):270-276.
[17] FONTAINE C,CLAES N,GRAAS M P,et al.Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg[J].Acta Clin Belg,2021,76(1):10-15.
[18] WEYCKER D,BENSINK M,LONSHTEYN A,et al.Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment[J].Curr Med Res Opin,2019,35(6):1073-1080.

聚乙二醇化重组人粒细胞刺激因子在造血干细胞移植后促进造血恢复的疗效分析

Treatment outcome of pegylated recombinant human granulocyte colony stimulating factor to promote hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation(allo-HSCT)

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	江和碧, 张晓红, 江华. 利妥昔单抗治疗造血干细胞移植后血小板输注无效的临床疗效[J]. 广州医药, 2018, 49(6): 13-16.
[2]	黎宇苗, 张玉平, 周铭, 莫文健, 毛平, 王顺清. 单倍体亲缘异基因造血干细胞移植治疗SAA 1例[J]. 广州医药, 2016, 47(3): 28-30.